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Abstract: Development of new anticancer drugs with currently available animal models is hampered
by the fact that human cancer cells are embedded in an animal-derived environment. Neuroblastoma
is the most common extracranial solid malignancy of childhood. Major obstacles include managing
chemotherapy-resistant relapses and resistance to induction therapy, leading to early death in very-
high-risk patients. Here, we present a three-dimensional (3D) model for neuroblastoma composed
of IMR-32 cells with amplified genes of the myelocytomatosis viral related oncogene MYCN and the
anaplastic lymphoma kinase (ALK) in a renal environment of exclusively human origin, made of human
embryonic kidney 293 cells and primary human kidney fibroblasts. The model was produced with
two pneumatic extrusion printheads using a commercially available bioprinter. Two drugs were
exemplarily tested in this model: While the histone deacetylase inhibitor panobinostat selectively
killed the cancer cells by apoptosis induction but did not affect renal cells in the therapeutically
effective concentration range, the peptidyl nucleoside antibiotic blasticidin induced cell death in both
cell types. Importantly, differences in sensitivity between two-dimensional (2D) and 3D cultures were
cell-type specific, making the therapeutic window broader in the bioprinted model and demonstrating
the value of studying anticancer drugs in human 3D models. Altogether, this cancer model allows
testing cytotoxicity and tumor selectivity of new anticancer drugs, and the open scaffold design
enables the free exchange of tumor and microenvironment by any cell type.
Keywords: bioprinting; cancer model; drug testing; neuroblastoma; panobinostat
1. Introduction
Bioprinting has been attracting a great deal of attention as a promising technology
to produce three-dimensional (3D) tissue models [1–4]. It allows the production of 3D
constructs with high spatial resolution by successively adding material in a layer-by-
layer manner. Most commonly, cell-laden hydrogels are used as bioinks that are rapidly
crosslinked after the printing procedure to maintain the desired structure [5]. With op-
timized hydrogel compositions, bioprinted cultures can be maintained for an extended
period of time while retaining high cell viability for the duration of the experiment [6].
Bioprinting technology is particularly suitable for the creation of tumor models,
as the high precision and reproducibility can recapitulate the tumor microenvironment
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(TME) [7,8]. In most animal models, human tumors are embedded in a xenogenic animal
environment [9]. This arrangement may produce results with limited relevance to human
pathophysiology. Bioprinting may help to overcome this shortcoming [10,11]. For exam-
ple, Langer et al. modeled tumor phenotypes, in which patient-specific tumor tissue was
surrounded by several stromal cell types [12]. Extrinsic signals and therapies altered the
tumor phenotypes, and the printed model was used to investigate interaction between
cancer cells and their microenvironment, demonstrating the potential of bioprinting for the
development of new anticancer drugs.
The present study focuses exemplarily on neuroblastoma, which is the most common
extracranial solid tumor of childhood that derives from developing and incompletely com-
mitted precursor cells from neural-crest tissues [13–15]. Despite progress in the treatment
and the use of multi-modal therapy, survival rates of high-risk neuroblastoma patients
are still low [16]. Dysregulation of the transcription factor MYCN is associated with poor
prognosis [17]. Amplification of this proto-oncogene acts as a single oncogenic driver
towards high-risk neoplastic transformation [18]. Panobinostat is a potent histone deacety-
lase (HDAC) inhibitor approved by the U.S. Food and Drug Administration (FDA) for the
treatment of multiple myeloma and is currently under investigation against various other
cancer types [19]. As an additional important factor, forkhead-box-protein O3 (FOXO3) was
found to be an important regulator of homeostasis that promotes tumor growth under hy-
poxic conditions and tumor angiogenesis in late-stage neuroblastoma [20]. Further targets
in high-risk neuroblastoma include the telomerase reverse transcriptase (TERT) and the
oncogene ALK [21,22]. Phosphoglycerate dehydrogenase (PHGDH) is a suitable marker for
risk stratification, as it is highly upregulated in high-risk MYCN-amplified neuroblastoma;
however, its inhibition by small molecule inhibitors antagonized chemotherapy efficiency
in patient-derived xenografts in mice [23]. In a recent study by Almstedt et al., 80 targets
were found to be associated with the risk of neuroblastoma, and differentiation signatures
and candidates for the treatment of high-risk neuroblastoma were identified [24].
Neuroblastomas have a high potential to migrate and can metastasize to almost any
organ. Around 60% of patients with neuroblastoma develop metastases, most commonly in-
volving bone marrow or cortical bone [25]. Although renal metastasis from neuroblastoma
is rather rare, cases have been reported [26–28]. Especially for bilateral renal metastases or
multiple renal metastases, local therapeutic options for the kidneys, such as nephrectomy
and/or radiotherapy, are infeasible, as they can cause complete loss of renal function
in patients [29]. Over the years, little improvement in the treatment for neuroblastoma
renal metastasis has been obtained and progress in understanding of the disease and the
development of new therapeutic strategies are urgently awaited.
The aim of the present study was to develop a bioprinted 3D model that mimics a
tumor in a microenvironment exclusively composed of human cells. As neuroblastoma
cells have been shown to be well suited for bioprinting approaches [30–35], this tumor
type was chosen as an example. To the best of our knowledge, few studies exist that
have embedded the tumor cells in an environment of normal cells to test the efficiency
and specificity of cytostatic or other anticancer drugs. Our study describes the creation
of a renal neuroblastoma model, in which the neuroblastoma cells were surrounded by a
microenvironment made up of human kidney cells. It can thus be regarded as a simplified
metastasis model. The model was created with a commercially available printer to allow
simple reproduction by other groups. We demonstrate that it can distinguish between
cancer-specific drugs and substances with general cytotoxicity and can thus be used for the
development of new cancer drugs or personalized treatment strategies. It can also be seen
as a model to reflect neuroblastoma infiltration into the kidney, as this process presents a
major medical problem, and if patients are poor responders to chemotherapy, nephrectomy
can be indicated.
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2. Results
2.1. Drug Treatment of Mono-Cell Type 3D Culture
The first step in the development of a cancer model was to characterize the individual
drug-sensitivity of the employed cell types. For the initial experiments, the neuroblas-
toma cell line IMR-32 and the human embryonic kidney 293 cells (HEK293) were printed
into simple 3D grid-like structure (Figure 1a) in a gelatin-alginate bioink as previously
described [36].
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constructs were treated with varying concentrations of the cancer drug panobinostat one 
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(2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) after 24, 
48, and 72 h. Dose–response curves show a significantly lower sensitivity of HEK293 cells 
towards panobinostat treatment compared to IMR-32 cells (Figure 2a,b). While the IC50 
values of IMR-32 cells were in the low nanomolar range, they were in the range of 
hundreds of nanomolar for HEK293 cells (Figure 2b,d and Table 1). 
Figure 1. Schematic representation of the 3D printed constructs designed for the present study. For
the initial experiments a simple grid-like structure was used (a), while the cancer model (b) consisted
of a core of neuroblastoma cells (cyan) surrounded by healthy kidney cells (pink).
As a proof-of-concept of the bioprinted cancer model for use in drug testing, the
constructs were treated with varying concentrations of the cancer drug panobinostat one
day after the printing procedure. Relative cell viabilities were determined with XTT assays
(2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) after 24, 48,
and 72 h. Dose–response curves sho a significantly lo er sensitivity of HEK293 cells
towards panobinostat treatment compared to IMR-32 cells (Figure 2a,b). While the IC50
values of I -32 cells were in the low nanomolar range, they were in the range of hundreds
of nanomolar for HEK293 cells (Figure 2b,d and Table 1).
Table 1. IC50 values of HEK293 and IMR-32 cells treated with panobinostat or blasticidin in 3D
constructs or 2D culture.
3D Bioprinted 2D Monolayer
HEK293 IMR-32 HEK293 IMR-32
Panobinostat
(nM)
24 h >1000 7.5 ± 0.1 >1000 4.9 ± 0.7
48 h 509.0 ± 83.8 3.5 ± 0.5 40.5 ± 12.8 2.7 ± 0.5
72 h 107.0 ± 40.1 2.1 ± 0.5 38.5 ± 7.8 2.5 ± 0.9
Blasticidin
(µM)
24 h 44.3 ± 41.6 52.9 ± 15.2 7.9 ± 1.4 9.0 ± 2.8
48 h 22.3 ± 9.1 21.9 ± 11.3 5.6 ± 0.1 5.2 ± 2.6
72 h 15.1 + 6.5 12.4 ± 8.0 5.0 ± 1.1 3.9 ± 2.2
For comparison, we tested the effects of blasticidin, which is an unspecific antibiotic
substance that inhibits translation [37]. As can be seen in Figure 2c, dose–response curves
of HEK293 and IMR-32 cells were similar for blasticidin. IC50 values of both cell types were
comparable and did not have significant differences at the time points under investigation
(Figure 2d and Table 1).
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Figure 2. Sensitivity of 3D cultured HEK293 and IMR-32 cells towards panobinostat and blasticidin.
HEK293 and IMR-32 cells were printed in a gelatin-alginate hydrogel (5 × 106 cells/mL) in 48-well
plates and treated with either panobinostat or blasticidin. Dose–response curves of bioprinted
HEK293 and IMR-32 cells after treatment with panobinostat (a) or blasticidin (c) for 24, 48, and
72 h are shown. The calculated IC50 values for both cell types are compared for panobinostat in
(b) and for blasticidin in (d). Data are presented as mean ± standard error of the mean; n = 3.
* p < 0.05, *** p < 0.001, **** p < 0.0001.
2.2. Cytotoxicity in 3D Constructs
Cytotoxicity can be directly monitored in 3D constructs to assess the cytostatic impact
caused by panobinostat on bioprinted cells. HEK293 and IMR-32 cells were separately
printed in grid models and treated with varying concentrations of panobinostat. After
72 h, the ratio of live (green channel) and dead (red channel) cells in the constructs was
monitored by fluorescence microscopy using a cytotoxicity assay (Figure 3a,b). Percentages
of live and dead cells, resulting from quantification of green and red fluorescence signals,
were calculated by the software ImageJ (Figure 3c,d). More than 75% of printed HEK293
cells survived using panobinostat concentrations of up to 50 nM, and only the highest doses
led to an obvious increase of dead cells (Figure 3a,c). In contrast, panobinostat began cell
killing at much lower doses and resulted in death of almost all IMR-32 cells already at a
concentration of 10 nM and above (Figure 3b,d).
2.3. Cell Sensitivity in 2D Culture
To figure out the influence of th 3D arrangement of the cells, we compared the IC50
values obtained in the bioprinted models with those from 2D monolayer cultu s. The 2D
cultures were challenged with a single dose of either panobinostat at varying concentrations
and cultured for 72 h. During the culture period, relative cell viability was monitored by
XTT assays (Figure 4) and used to calculate the IC50 values from the dose–response curves
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(Table 1). As observed for the 3D cultures, IMR-32 cells were substantially more sensitive
to panobinostat treatment than HEK293 cells, and viability was significantly decreased at
concentrations in the low nanomolar range starting as early as 24 h post treatment. After
48 and 72 h of cultivation, the decrease in viability became even more pronounced and
at concentrations above 15 nM of panobinostat, virtually no viable cells were detected.
Accordingly, IC50 values of IMR-32 cells challenged with panobinostat were in the low
nanomolar range and substantially lower than that of HEK293 cells (Table 1).
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Figure 3. Cytotoxicity of HEK293 cells and IMR- 2 cells in printed constructs after treatment with
panobinostat. Cytotoxicity ssa s of 3D-bioprinted HEK293 cells (a) and IMR-32 cells (b) after
treatment with panobinostat for 72 h (living cells in green, dead cells in red; all images were taken
at the same magnification, scale bar, 250 µm), and the estimated percentages of living and dead
cells (c,d).
These results were confirmed by cytotoxicity assays (Fi ur S1), whi h clearly dis-
played differences in sensitivity of HEK293 an IMR-32 cells t wards panobi stat treat-
ment. While HEK293 cells were virtually insensitive to the panobinostat treatment in the
concentration range tested, the fraction of green fluorescence from viable IMR-32 cells
drastically decreased at panobinostat concentrations above 5 nM.
The most interesting outcome of the comparison was that the IC50 values of IMR-
32 cells for panobinostat were approximately one order of magnitude higher for the 3D
cultures than for the 2D monolayers. The differences were less pronounced for HEK293 cells
so that the therapeutic window was broader in the bioprinted constructs, i.e., the difference
in sensitivity between both cell types was more pronounced in 3D culture (approximately
two orders of magnitude) than in 2D culture (roughly one order of magnitude).
As the study intended to investigate the specificity of treatment for cancerous cells,
we also tested whether co-cultivation of both cell types in 2D influences the sensitivity to-
wards panobinostat. To this end, HEK293 cells stably expressing green fluorescence protein
(HEK293-GFP) and IMR-32 cells were seeded together at a ratio of 1:1. After treatment
with panobinostat, cells were analyzed by an immunofluorescence microscopy (Figure 5).
The green fluorescence emitted by HEK293-GFP cells was used to simplify this analysis.
IMR-32 cells were labeled by immunofluorescence staining against human disialoganglio-
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side GD2 (GD2, red channel), which is expressed on tumors of neuroectodermal origin,
including neuroblastoma and melanoma [38,39]. Nuclear counterstaining was performed
with DAPI (4′,6-diamidin-2-phenylindol, blue channel). As shown in Figure 5, HEK293-
GFP and IMR-32 cells occupied approximately equivalent areas in the untreated control
group after 72 h. With increasing panobinostat doses, the area with red signals, which
represents the GD2-stained IMR-32 cells, shrank gradually, whereas green fluorescing
HEK293 cells occupied the vacated area. Only at the highest concentration of panobinostat
tested (50 nM), was a decrease in HEK293-GFP cells observed, while virtually no more
IMR-32 cells were detectable.
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HEK293 (104 cells/well) and IMR-32 cells (104 cells/well) were separately seeded in 96-well plates and
treated with either panobinostat or blasticidin. Dose–response curves of HEK293 and IMR-32 cells
after treatment with panobinostat (a) or blasticidin (c) 24, 48, and 72 h post treatment; and the
calculated IC50 values of HEK293 and IMR-32 cel s for indicated time points, (b) for panobinostat
and (d) for blasticidin. Data are presented as mean ± standard error of the mean; n = 3. ** p < 0.01,
*** p < 0.001.
Similar to the 3D constructs, the sensitivity of the cells in 2D monolayers for blasticidin
was also tested. As previously observed, dose–response curves and calculated IC50 values
were similar for both cell types and did not show significant differences at the time points
under investigatio (Figure 4c,d and Table 1).
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Figure 5. Co-culture of HEK29-GFP cells and IMR-32 cells in monolayer treated with panobinostat
visualized by expressed GFP and immunofluorescence staining of GD2. HEK293-GFP cells and IMR-
32 cells (1:1) at a total density of 104/well were seeded in 96-well plate and dosed with panobinostat
at the indicated concentrations for 72 h. HEK293-GFP cells (green) expressed GFP while IMR-32 (red)
cells were labeled by GD2 immunofluorescence staining. The nuclei were all stained with DAPI in
blue. All images were taken at the same magnification; scale bar, 250 µm.
2.4. Induction of Apoptosis in 2D Culture
Panobinostat is known to be an HDAC inhibitor, so our next aim was to confirm
observation of this mode of action in our experimental set-up. This activity may result
in the induction of apoptosis. We therefore investigated whether panobinostat treatment
of HEK293 and IMR-32 cells in 2D culture produced cleaved caspase-3 (green channel
in Figure S2) by immunofluorescence staining. Additionally, cellular filamentous actin
(F-actin, red channel) and nuclei (blue channel) were visualized by phalloidin and DAPI
counterstaining, respectively. Staining of F-actin and the nuclei revealed that increasing
panobinostat concentrations led to decreasing numbers of IMR-32 cells but did not impact
HEK293 cell numbers, which was in agreement with the results of XTT and cytotoxicity
assays. Cleaved caspase-3 was not detected in HEK293 cells at panobinostat concentrations
below 25 nM, and even 50 nM panobinostat resulted in only weak signals. In contrast, sig-
nals resulting from cleaved caspase-3 were detected in IMR-32 cells, even at concentrations
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as low as 5 nM, and became more pronounced at higher concentrations in a dose-dependent
manner. This demonstrates that panobinostat is a stronger inducer of apoptosis in IMR-32
cells than in HEK293 cells.
2.5. Bioprinting and Drug Treatment of Cancer Model
After the initial characterization of the drug activity, a cancer model was fabricated
that consisted of a cancerous core (IMR-32 cells) surrounded by a shell of kidney cells as
illustrated in Figure 1b. In the initial experiments, HEK293-GFP cells were used for better
visualization, then HEK293 cells were included to provide additional immunofluorescence
evidence and in the final experiments primary kidney fibroblasts were used to increase the
physiological significance of the model. The diameter of the inner core was 3 mm, while
the total model was 6 mm in diameter and 0.4 mm in height (Figure 6a). A set of 48 such
constructs were produced by bioprinting and proved to be highly reproducible (Figure 6b).
Fluorescence analyses revealed a clear boundary between the IMR-32 cell in the cen-
ter and the green fluorescing HEK293-GFP cells (Figure 6c). The model was treated with
panobinostat for 72 h and dead cells were stained with ethidium homodimer-1. Pronounced
red fluorescence of dead cells was detected coming from the inner part composed of IMR-32
cells, while strong green fluorescence in the outer ring resulted from high GFP expression
of the stably transfected HEK293-GFP cells. Only at very high panobinostat concentrations
(1000 nM) was a fraction of dead, red fluorescent HEK293-GFP cells observed. The sig-
nificantly higher sensitivity of the neuroblastoma cells towards panobinostat was clearly
confirmed in the quantitative analysis of the red fluorescence of the inner and outer part of
the model, respectively (Figure 6d). Two conclusions can be drawn from these observations:
The bioink composition allows maintenance of the intended design of the model with a
cancerous core surrounded by a shell of kidney cells, and the differences in drug sensitivity
can be clearly seen in a 3D model composed of different cell types.
The experiments were repeated with HEK293 and IMR-32 cells, as this approach allows
the detection of living cells by calcein AM staining, which cannot be distinguished from the
green fluorescence of HEK293-GFP cells. These experiments confirmed the observations
made above (Figure S3). A concentration of panobinostat as low as 10 nM was sufficient
to kill a substantial fraction of IMR-32 cells. The merged images show a clear border
between the dead, red fluorescing cells in the center and green living cells in the outer ring
at panobinostat concentrations of 10 to 100 nM. Red fluorescence originating from dead
HEK293 cells was only observed at very high panobinostat concentrations.
The next experiment aimed at investigating the induction of apoptosis in the different
parts of the cancer model by immunofluorescent labeling of cleaved caspase-3 (Figure S4,
green channel). To clearly distinguish HEK293 cells from IMR-32 cells in the printed cancer
models, the latter were labeled with the neuroblastoma-specific GD2 antibody (red channel).
Nuclear counterstaining with DAPI (blue channel) revealed a homogenous distribution of
the cells throughout the constructs for all samples (Figure S4a,b). Starting at a panobinostat
concentration of 10 nM, green fluorescence indicating the induction of apoptosis became
visible in the cancerous core of the constructs. Signal intensity increased at higher drug
concentrations. In contrast, even at the highest concentration of panobinostat of 1000 nM,
only a weak green signal originating from cleaved caspase-3 was observed in the periphery
of the model containing HEK293 cells. Quantification of the fluorescence signals using
ImageJ revealed significant differences between the presence of cleaved caspase-3 in the
cancer part and surrounding renal environment (Figure S4c). Thus, induction of apoptosis
is significantly stronger by a factor of two to three in IMR-32 cells compared to that in
HEK293 cells.
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ner. (c) The cancer model was treated with panobinostat for 72 h and subsequently stained with 
ethidium homodimer-1. HEK293-GFP cells emitted green fluorescence, dead cells were identified 
by ethidium homodimer-1 staining in red. The boundary between both cell types is indicated by a 
dotted line. All images were taken at the same magnification; scale bar, 500 µm. (d) Quantitative 
analysis of dead cells in HEK293-GFP and IMR-32 parts of the models by mean fluorescence inten-
sity based on the red channel results. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 6. Cancer model d cytotoxicity assays following treatment with panobinostat. ( ) The
bioprinted cancer model consiste of a core of neuroblastoma IMR-32 cells (diameter of 3 mm, height
of the construct 0.4 mm) surrounded by an environment of kidney cells (HEK293-GFP cells in these
experiments, HEK293 cells and primary kidney fibroblasts, respectively, in experiments below, outer
diameter is 6 mm). (b) Bioprinting can produce the constructs in a highly reproducible man er.
(c) The cancer model was treated with panobinostat for 72 h and subsequently stain d with ethidium
homodimer-1. HEK293-GFP cells emitted green fluorescence, dead cells were identified by ethidium
homodimer-1 staining in red. The boundary between both cell types is indicated by a dotted line. All
images were taken at the same magnification; scale bar, 500 µm. (d) Quantitative analysis of dead
cells in HEK293-GFP and IMR-32 parts of the models by mean fluorescence intensity based on the
red channel results. * p < 0.05, ** p < 0.01, *** p < 0.001.
A completely diffe nt picture arose for blasticidin treatment. H re, no fluoresc nce
originating from cleaved c sp se-3 was observed at concentrati ns up to 10 µM (Figure S4b).
At higher concentrations, the signal became stronger in a dose-dependent manner in both
parts of the model. Quantitative analysis of the fluorescence by ImageJ confirmed the
blasticidin-sensitivity of both cell types is roughly equivalent (Figure S4d). The model thus
allows distinguishing drugs which are specifically toxic to cancer cells like panobinostat
from those that are generally cytotoxic such as blasticidin.
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2.6. Cell Response of Primary Human Kidney Fibroblasts on Panobinostat Treatment
Despite the ambiguities about the origin of the HEK293 cell line and its derivatives,
they are among the most widely used cells in molecular biology, after HeLa cells [40]. To
improve the (patho-)physiological relevance of the bioprinted cancer model, we replaced
the HEK293 cells with human primary kidney fibroblasts, expecting them to provide a
physiologically more relevant human renal microenvironment for the cancer cells. Fibrob-
lasts are important regulators for the maintenance of tissue cohesion, as they are essential
for the production and degradation of extracellular matrix components [41]. In addition,
kidney fibroblasts also have endocrine activity [42].
For an initial characterization of their drug sensitivity, human kidney fibroblasts were
seeded in a 96-well plate and treated with panobinostat. Cell viability, as evaluated by XTT
assay, remained above 90% 24 h post treatment for all concentrations tested (Figure 7a).
Only at later time points (48 and 72 h after panobinostat treatment), was a dose-dependent
decrease in viability detected. The IC50 values were calculated and found to be comparable
to the ones of HEK293 cells in 2D culture (Figure 7b and Table 2). Similar characteristics
were observed when primary human kidney fibroblasts were printed into a 3D structure
(Figure 7c,d). Compared to the IC50 values of the printed IMR-32 cells (see above, Table 1),
IC50 values for the primary fibroblasts were approximately two orders of magnitude higher
(Table 2). Resistance of human kidney fibroblasts to panobinostat was also found in
cytotoxicity assay for 2D and 3D cultures (Figure S5).
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Figure 7. Dose–response curves for panobinostat treatment of primary human kidney fibroblasts in 2D
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Table 2. IC50 values of human kidney fibroblast treated with panobinostat in 2D culture or
3D constructs.
2D Monolayer 3D Bioprinted
Panobinostat
(nM)
24 h >1000 >1000
48 h 120.3 ± 44.3 328.2 ± 98.5
72 h 35.5 ± 19.8 158.9 ± 40.5
2.7. Effect of Panobinostat on Printed Cancer Model with Neuroblastoma and Primary
Kidney Fibroblasts
In the final experiment of this study, primary human kidney fibroblasts were printed
in the cancer model described above, i.e., the center containing IMR-32 neuroblastoma cells
was surrounded by a ring of primary fibroblasts. The model was treated with increasing
concentrations of panobinostat, and cytotoxicity assays were carried out 72 h thereafter.
As can be seen in Figure 8, red fluorescence originating from dead cells appeared in the
cancerous part starting at 10 nM panobinostat and became more intense at increased drug
concentrations. In contrast, dead fibroblasts were only observed at high concentrations
of panobinostat.
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3. Discussion
Despite substantial progress in the last few decades, efficient treatment options are
still lacking for many tumor types and especially for metastatic cancer. In preclinical
studies, 2D monolayer cultures have greatly contributed to the basic knowledge of genetic
factors that drive transformation of somatic cells into tumor cells. These studies, however,
cannot mimic the 3D architecture of tumors and their interaction with their surrounding
microenvironment. To this end, animal models were developed which allowed studying
tumor development in a complex pathophysiological environment [9]. Although these
models made an enormous contribution to the field, they provide a xenogenic microen-
vironment instead of a human one, and therefore often have limited relevance to human
pathophysiology [43]. As a consequence, the average success rate for the translation of
insights from animal models to clinical trials is less than 8% [44]. In line with these data, a
comprehensive review revealed a failure rate of drug candidates in oncology of 97% [45].
Alternative strategies with higher predictivity for newly developed drug candidates are
thus urgently required.
Although still being a comparatively young discipline, bioprinting technologies have
already demonstrated their potential for cancer research [7] and the printability of neu-
roblastoma cells has been demonstrated in several studies: The Noguera group produced
bioprinted neuroblastoma models and investigated the impact of tissue stiffness, which
commonly increases in solid tumors [30,31]. Remarkably, they found stiffness to influence
expression patterns and cellular physiology. In a model composed of the neuroblastoma cell
line SH-SY5Y in co-culture with mesenchymal stromal cells and human primary umbilical
vein endothelial cells, the neuroblastoma cells formed Homer Wright-like rosettes and
maintained their proliferative capacities [34]. Another bioprinted tumor model consisting
of SK-N-BE(2) cells was used to investigate the infiltration of chimeric antigen receptor
(CAR) T cells into tumor tissues [35]. In further studies, neuroblastoma cell lines have
been used to develop neural tissue for studying neurodegenerative diseases [32,33]. None
of these previous studies, however, tested cytostatic or other anticancer drugs in the bio-
printed models. As the printability of neuroblastoma cells has been well documented, we
chose this tumor type as an example for our open design of a cancer model to test the
activity and specificity of anticancer drugs. Our model was produced with a commercially
available bioprinter and can therefore easily be adapted by other research groups.
The TME has a major influence on the solid tumor, as it provides cytokines, immune
cells, and vasculature that determine the tumor phenotype and encumber therapeutic
interventions [46,47]. Due to species differences, the effects of the TME measured in animal
models cannot be relied upon when translated into clinical settings. In contrast, bioprinting
can be used to produce a tumor in a human TME and to investigate interactions between
the tumor and its TME, as well as its influence on drug treatment, for neuroblastomas and
other types of tumors [48]. In breast cancer, tumor progression is strongly influenced by its
microenvironment and particularly by interaction of the cancer cells with adipose tissue,
which can be recapitulated in bioprinted models [49]. In another study, breast cancer cells
were printed in the center of a 3D model and surrounded by adipose-derived mesenchymal
stem/stromal cells (ADMSC) [50]. This model was significantly less sensitive to treatment
with doxorubicin than a construct that contained the cancer cells only. The response was
found to depend on the thickness of the ADMSC layer, demonstrating the importance of
the tumor environment. In a previous study, we found a bioprinted liver model to be less
sensitive toward Aflatoxin B1 than a monolayer culture [51]. The possibility of creating
sustainable long-term cultures allows the study of the long-term mutagenic effects of a
potential carcinogen. Heterogenous tissue models with high cell density can be produced
by bioprinting technologies, including spheroids [52].
The current lack of standards for models and their reproducibility makes it difficult to
compare the results from different research groups. For example, Langer et al. produced a
tumor model, as described above, in which cancer cells were printed in a stromal mix of
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human fibroblasts and endothelial cells [12]. This model studied interactions between the
tumor and its microenvironment; however, the sophisticated model was produced with
a special printer of the company Organovo, Inc. to which other researchers do not have
access. In contrast, the model presented here can easily be reproduced with an affordable,
commercially available printer.
In our study, we evaluated the sensitivity of the neuroblastoma cells IMR-32 and
renal HEK293 cells, as well as primary kidney fibroblasts, toward the anticancer drug
panobinostat and the cytotoxic substance blasticidin in 2D and 3D cultures. IMR-32 cells
had comparable sensitivities for panobinostat in 2D and 3D cultures, whereas HEK293 and
primary kidney fibroblasts became more resistant, when cultured in the 3D model. Most
importantly, IMR-32 cells were substantially more sensitive to panobinostat treatment than
the renal cells. The difference was approximately one order of magnitude in 2D culture
and increased to roughly two orders in magnitude in bioprinted models. In contrast, the
effect of blasticidin treatment was comparable for IMR-32 and HEK293 cells and the IC50
values increased for both cell types in 3D compared to 2D in a similar manner.
The bioprinting technology was then used to produce neuroblastoma in a renal en-
vironment. Fluorescence microscopy confirmed that the chosen bioinks maintained the
intended structure over the course of the experiments for 72 h. Cytotoxicity assays showed
that intermediate panobinostat concentrations of 10–100 nM selectively killed neuroblas-
toma cells, while leaving the kidney cells intact. Cell death occurred via the induction of
apoptosis, as demonstrated by measuring increased levels of cleaved caspase-3. In contrast
to panobinostat, blasticidin induced apoptosis in both cell types at similar concentrations.
As HEK293 cells are easy to culture and expand to large numbers, they were used
for the initial experiments. This cell line is widely used, but its exact origin is still contro-
versial [40]. While they have been considered kidney epithelial cells or fibroblasts, their
karyotype is unstable, and they are tumorigenic. We therefore used primary kidney fibrob-
lasts in further experiments. These tests confirmed findings obtained with HEK293 cells.
IMR-32 cells are approximately two orders of magnitude more sensitive to panobinostat
treatment in the cancer model than the kidney cells and can thus be selectively killed by
the anti-tumor drug.
As described above, the study of Grundwald et al. [35] used a bioprinted neuroblas-
toma model consisting of SK-N-BE(2) cells to investigate tumor tissue penetration by CAR T
cells. Our model, which consists of not only cancerous cells, but also normal fibroblasts, can
now be used to investigate the specificity of the treatment for the destruction of the tumor.
The next step will therefore be to use the model consisting of neuroblastoma in a microen-
vironment composed of non-cancerous cells, not only for cytostatic substances but also
for immunotherapeutic approaches. Another interesting option is to use patient-derived
tumor cells to develop a personalized treatment strategy. For example, Mao et al. produced
a 3D tumor model with patient derived intrahepatic cholangiocarcinoma cells [53], and
Flores–Torres et al. developed a patient-derived 3D bioprinted spheroid model with triple-
negative breast cancer cells [54]. These studies, however, used the cancer cells only, while
the strategy presented here will allow to study the patient-derived cells in a human TME.
While we focused the present study on the production of an advanced cancer model
involving a tumor surrounded by a human microenvironment, at the same time we aimed
to support the principles of replacement, reduction, and refinement (3R principles). Highly
sophisticated 3D organ models will help to replace animal experiments with in vitro stud-
ies [55]. It is our strong belief that only innovative new tissue engineering strategies en-
abling better transferability of research results to the human (patho-)physiology will bring
us closer to the ultimate goal to reduce the number of animals used for experimental purposes.
4. Materials and Methods
4.1. Cell Culture
Human embryonic kidney 293 cells (HEK293, CRL-1573) were purchased from Amer-
ican Type Culture Collection (ATCC, Manassas, VA, USA) and the neuroblastoma cell
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line IMR-32 from the German Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany). HEK293-GFP cells were obtained from GenTarget (SC001, San
Diego, CA, USA). Human kidney fibroblasts were purchased from Innoprot (P10666, De-
rio, Bizkaia, Spain). All cell lines were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Biowest, Nuaillé, France) containing 10% fetal bovine serum (FBS; c.c.pro, Ober-
dorla, Germany), 2.5 mg/mL of glucose (Biowest, Nuaillé, France), 2 mM of L-glutamine
(Biowest, Nuaillé, France), 1% non-essential amino acids (NEAA, Biowest, Nuaillé, France),
and 1% penicillin-streptomycin (Biowest, Nuaillé, France) and maintained at 37 ◦C in hu-
midified atmosphere with 5% CO2. When confluent, the cells were washed with phosphate
buffered saline (PBS, Biowest, Nuaillé, France) and then harvested using trypsin-EDTA
(Biowest, Nuaillé, France).
4.2. Bioprinting
The hydrogel, consisting of 6.67% gelatin (Sigma–Aldrich, St. Louis, MO, USA) and
4.5% sodium alginate (Sigma, Shanghai, China), was prepared in DMEM under continuous
stirring at 37 ◦C overnight as described before [36,56]. Prior to the printing process, the
printable cell-laden bioink was obtained by mixing the hydrogel, CaSO4 (Roth, Karlsruhe,
Germany), and the cell suspension, so that the final concentration of each component
was: 3% gelatin, 2% sodium alginate, 30 mM of CaSO4, and 5 × 106 cells/mL bioink.
After physical pre-crosslinking for 8 min at room temperature, the cell-laden bioink was
transferred into a pneumatic cartridge.
The 3D constructs were fabricated in a 48-well plate using a multi nozzle bioprinting
system (Bio X, Cellink, Gothenburg, Sweden) as the bioink was extruded from a 22 G
conical tip under pneumatic pressure. A double-layer grid-like model with a side length
of 8 mm was printed for single-cell type printing, while a concentric disc construct with
a 3 mm-diameter inner part containing cancer cells, and 6 mm-diameter outer part con-
taining normal stromal cells was fabricated for the two-cell type cancer model. After the
printing process, printed models were submerged in 100 mM of CaCl2 for 10 min at room
temperature. Afterwards, the 100 mM CaCl2 solution was replaced with 300 µL of complete
medium supplemented with 20 mM CaCl2 per well, and subsequently the constructs were
cultured at 37 ◦C and 5% CO2.
4.3. Drug Treatment of Cancer Models
For monolayer culture, cells were seeded into a collagen (90 µg/mL, collagen type I, rat
tail, EMD Millipore, Billerica, MA, USA) -coated 96-well plate at a density of 104 cells/well.
After culture for 24 h, the supernatant of each well was replaced by 100 µL of medium with
the respective drug (panobinostat ((LBH589, Selleckchem, Houston, TX, USA), initially
dissolved in dimethyl sulfoxide (DMSO, Sigma–Aldrich, St. Louis, MO, USA)) or blasticidin
(10 mg/mL in 20 mM HEPES, Sigma–Aldrich, St. Louis, MO, USA)) at the indicated
concentrations. Complete medium was used for the untreated control group.
For the 3D bioprinted constructs, complete medium was supplemented with 20 mM
of CaCl2 and drugs at the given concentration range were used to treat the samples. The
constructs cultured in complete medium supplemented with only 20 mM of CaCl2 served
as untreated group.
4.4. Cell Viability Assay
Cell viability of the cultures was determined by XTT assays (2,3-Bis-(2-Methoxy-4
-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide, Alfa Aesar, Ward Hill, MA, USA)
that measured metabolization of the tetrazolium salt at various time points following the
treatment. Briefly, a mixture of 50 µL XTT reagent (1 mg/mL in RPMI, Biowest, Nuaillé,
France) and phenazine methosulfate (PMS, 3.83 mg/mL in PBS, AppliChem, Darmstadt,
Germany) at a volume ratio of 500:1 was added to each well of a 96-well plate for 2D cell
culture and allowed to incubate for 4 h at 37 ◦C and 5% CO2. The absorbance was measured
at wavelengths of 450 and 620 nm (for reference) using a microplate reader (Sunrise, Tecan,
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Männedorf, Switzerland). For 3D constructs, 150 µL of XTT/PMS reagent mixture was
added for 4 h, and the absorbance of the supernatant was measured as mentioned above.
Cell-free constructs were used as a background. The relative cell viability was calculated
by the following formula:
relative cell viability =
Absorbancetest well −Absorbancebackground well
Absorbancecontrol well −Absorbancebackground well
(1)
Afterwards, half maximal inhibitory concentration (IC50) values were calculated based
on the nonlinear regression curves of the dose–response data (dose–response curves) using
GraphPad Prism 8 (GraphPad, La Jolla, CA, USA). All experiments were performed at least
three times.
4.5. Cytotoxicity Assay
To analyze the cell status and cell distribution, a cytotoxicity assay was performed
using a viability/cytotoxicity kit (Thermo Fisher Scientific, Waltham, MA, USA) in ac-
cordance with the manufacturer’s instructions. The 2D cultured cells were incubated in
RPMI without phenol red, which contained 2 µM of calcein AM and 2 µM of ethidium
homodimer-1 for 10 min, while the 3D constructs were incubated for 30 min. The stained
samples were analyzed by fluorescence microscopy (Observer Z1, Zeiss, Jena, Germany).
The ratio of living and dead cells in 3D printed constructs was also analyzed using the
software ImageJ (1.53e, National Institutes of Health, Bethesda, MD, USA).
4.6. Immunofluorescence Staining
At predetermined time points, samples were washed with PBS and fixed in 4%
formaldehyde (Carl Roth, Karlsruhe, Germany) for 30 (2D) or 60 min (3D) at room tem-
perature. The samples were then permeabilized with 0.1% (v/v) Triton X-100 (Carl Roth,
Karlsruhe, Germany) for 10 (2D) or 30 min (3D), and blocked with 5% goat serum (Sigma-
Aldrich, St. Louis, MO, USA) for 30 (2D) or 60 min (3D), respectively. Afterwards, the
samples were incubated with primary antibodies (anti-human disialoganglioside GD2,
1:400, BD Pharmingen, Franklin Lakes, NJ, USA; Cleaved Caspase-3 antibody, 1:1000, Cell
Signaling, Danvers, MA, USA) at 4 ◦C overnight, washed three times with PBS, and subse-
quently incubated with the respective secondary antibodies (goat anti-mouse Alexa Fluor
594, 1:1000, Invitrogen, Carlsbad, CA, USA; goat anti-rabbit Alexa Fluor 488, 1:1000, Invit-
rogen, Carlsbad, CA, USA) at room temperature for 2 h. Afterwards, samples were again
washed with PBS three times prior to nuclear staining with 1 µg/mL of 4′,6-diamidino-
2-phenylindole (DAPI, Sigma–Aldrich, St. Louis, MO, USA) for 60 min. When indicated,
F-actin of cells was labeled with phalloidin (Alexa Fluor™ 488 Phalloidin, 1:400, Invitrogen,
Carlsbad, CA, USA) for 30 min at room temperature. Stained samples were analyzed by
the fluorescence microscopy.
4.7. Statistical Analysis
Results are shown as the means ± standard error of the mean from at least three
independent experiments. Statistical analyses were performed using GraphPad Prism 8
software. One-way ANOVA was utilized for analysis of variance to compare between
groups. Statistical significance was accepted at levels of * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001.
5. Conclusions
Taken together, we present a neuroblastoma model that can easily be adapted to other
cancer types as it allows replacing the cancer and surrounding cells with any cell type
of interest. It may also be used to test tumor cells from a specific patient and develop
a personalized treatment strategy. Two main conclusions can be drawn from our study:
Bioprinted tumor models composed of cancerous cells in a non-malignant environment
composed of human cells can be used to differentiate substances with a specific anticancer
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activity from those with general cytotoxic properties, and the sensitivity of cells towards
cytotoxic substances differs substantially in 2D and 3D culture.
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